Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
$13.51
-$0.26(-3.11%)
At close: 4:00 PM EST
$13.51
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $14.93
Previous CloseN/A
Volume155.59K
Average Volume (3M)623.88K
Market Cap
$666.71M
Enterprise Value$492.73M
Total Cash (Recent Filing)$274.20M
Total Debt (Recent Filing)$268.14M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Mar 03, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding50,623,085
10 Day Avg. Volume703,665
30 Day Avg. Volume623,884
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.47
Price to Sales (P/S)4.59
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit6.11
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$28.57Price Target Upside111.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.1
Revenue Forecast (FY)$198.55M
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesA larger DMD opportunity is anticipated for RegenXBio Inc. following clinical and regulatory setbacks by a competitor, which could allow RegenXBio to differentiate on safety and gain market share.
Product LaunchThe potential launch of a partnered product in the competitive wet AMD market could provide additional revenue opportunities and enhance the company’s financial standing.
Regulatory ApprovalsThere is a high likelihood of approval for RGX-121 in MPS II, which could strengthen the company's position and financial outlook.
Bears Say
Regulatory DelaysThe RGX-121 PDUFA was delayed primarily to review the submission of additional data requested by FDA.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $14.93 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $666.71M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Mar 03, 2026 which is in 73 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Nov 06, 2025. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.282 by $0.082.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -0.73.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,623,085 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.282. Following the earnings report the stock price went down -3.79%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.57 (111.47% Upside)
$28.57 (111.47% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 30.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.87%
12-Months-Change
Fundamentals
Return on Equity
-76.88%
Trailing 12-Months
Asset Growth
1.17%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and achievements in clinical development and financial positioning. However, there are regulatory challenges and uncertainties, particularly concerning international approvals and the use of external controls. Despite these challenges, the overall sentiment leans positive due to strong pipeline advancements and financial stability.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$28.57
▲(111.47% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.69% Insiders
18.45% Mutual Funds
20.27% Other Institutional Investors
38.69% Public Companies and Individual Investors